Overall, linagliptin significantly reduced the OGTT-associated glucose excursion by 18% (95% CI -26.55, -10.34) in the high GLP-1 group compared with 8% (95% CI -16.09 to 0.24) in the low GLP-1 group ( Figure 2C )
Both GIP and GLP-1 receptors are expressed throughout the gastrointestinal tract, and their activation produces multiple effects that can alter bowel function and stool consistency
Case reports include isolated cardiac events after stimulant supplement use - see a published case report of STEMI after supplement use for an example
rarely specific statins (simvastatin) or ACE inhibitors (captopril) Psychiatric medications : Phenothiazines (chlorpromazine), some tricyclic antidepressants, and rarely certain SSRIs Diabetes medications : Sulfonylureas (glipizide, glyburide) Retinoids : Isotretinoin and topical tretinoin for acne Antifungals : Griseofulvin and voriconazole Patients taking weight management medications like Zepbound may also be prescribed other agents for comorbid conditions such as hypertension or diabetes
At standard human doses (1 to 2 mg per day for a 70 kg person, or 0.014 to 0.028 mg/kg), copper toxicity risk is negligible